Efficacy and safety of hydroxychloroquine for treatment of mild SARS-CoV-2 infection and prevention of COVID-19 severity in pregnant and postpartum women: A randomized, double-blind, placebo-controlled trial.
Raquel GonzalezAnna GoncéMaría Del Mar GilEdurne MazaricoElena Ferriols-PérezPaloma ToroElisa LlurbaElisa SaézMiguel Ángel Rodríguez-ZambranoLaura García-OteroMarta LópezBelén SantacruzMª Ángeles RománAntonio PayàSofia AlonsoMonica Cruz-LeminiClara Pons-DuranLuis Bernardo HerreraHaily ChenAzucena BardajíLlorenç QuintóClara Menendeznull nullPublished in: Acta obstetricia et gynecologica Scandinavica (2023)
HCQ was found to be safe in pregnant and postpartum women with asymptomatic or mild SARS-CoV-2 infection. Although the prevalence of infection was decreased in the HCQ group, the statistical power was insufficient to confirm the potential beneficial effect of HCQ for COVID-19 treatment.
Keyphrases
- coronavirus disease
- sars cov
- double blind
- respiratory syndrome coronavirus
- pregnant women
- randomized controlled trial
- study protocol
- risk factors
- polycystic ovary syndrome
- adipose tissue
- metabolic syndrome
- combination therapy
- placebo controlled
- climate change
- risk assessment
- human health
- pregnancy outcomes
- replacement therapy
- breast cancer risk